Abstract:Background:Systemic sclerosis (scleroderma, SSc) is a systemic autoimmune disease characterized by inflammation, fibrosis and vasculopathy and associated with high mortality and high morbidity1. Stratification based on whole-genome gene expression data could provide a new basis for clinical diagnosis from a micro perspective2.Objectives:The objective of this study is to stratify patients with SSc, combine with clinical skin scores and clinical features, and provide a preliminary assessment and novel insights for assessing disease severity, and treatment design.Methods:The original data mRNA expression profiles of GSE95065 (including 18 SSc patients and 4 healthy controls) and GSE130955 (including 58 SSc patients and 33 healthy controls) were downloaded from the public Gene Expression Omnibus (GEO) database. After batch correction, background adjustment, and other pre-processing, a large gene matrix was obtained to identify the differently expressed genes (DEGs) of SSc compared with healthy controls. Then the gene expression matrix decomposition was used to identify SSc subtypes by NMF algorithm. The cluster-based signature genes were applied to pathway enrichment analysis by Metascape3. Immune infiltrating cells and clinical skin scores were evaluated in all SSc subtypes.Results:Total 325 DEGs were imputed to NMF unsupervised machine learning algorithm. Patients were divided into 2 subtypes (Figure 1A), one of which (sub1) was mostly enriched in the defense response to bacterium and cellular response to lipopolysaccharide pathway and another subtype (sub2) was enriched in the PPAR signaling and alcohol metabolic process pathway (Figure 1B-C). According to immune infiltration, sub1 had higher level of immune cells such as B cells, CD4+T cells, DC cells, Th2 cells and Tregs compared with sub2 (P < 0.01). Sub2 had more skin-related cells, including Epithelial cells, Fibroblasts and Sebocytes (P < 0.05). Interestingly, combined with clinical information, sub1 showed a severe clinical skin score over those of Sub2 patients (P < 0.05)(Figure 1D-E).Conclusion:Our findings indicated that SSc patients could be stratified into 2 subtypes which had different molecular profiles of disease progression and clinical disease activities. This result could serve as a template for future studies to design stratified approaches for SSc patients.References:[1]Xu X, Ramanujam M, Visvanathan S, et al. Transcriptional insights into pathogenesis of cutaneous systemic sclerosis using pathway driven meta-analysis assisted by machine learning methods. PLoS One 2020;15(11):e0242863. doi: 10.1371/journal.pone.0242863 [published Online First: 2020/12/01].[2]Xu C, Meng LB, Duan YC, et al. Screening and identification of biomarkers for systemic sclerosis via microarray technology. Int J Mol Med 2019;44(5):1753-70. doi: 10.3892/ijmm.2019.4332 [published Online First: 2019/09/24].[3]Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 2019;10(1):1523. doi: 10.1038/s41467-019-09234-6 [published Online First: 2019/04/05].Acknowledgements:This project was supported by National Science Foundation of China (82001740), Open Fund from the Key Laboratory of Cellular Physiology (Shanxi Medical University) (KLCP2019) and Innovation Plan for Postgraduate Education in Shanxi Province (2020BY078).Disclosure of Interests:None declared

Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels

Classical Disease-Specific Autoantibodies In Systemic Sclerosis: Clinical Features, Gene Susceptibility, And Disease Stratification

Immune Profiling of Patients with Systemic Sclerosis through Targeted Proteomic Analysis

Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment

Comprehensive autoantibody profiles in systemic sclerosis: Clinical cluster analysis

Biomarkers reflecting the pathogenesis, clinical manifestations, and guide therapeutic approach in systemic sclerosis: a narrative review

Biomarkers in Systemic Sclerosis: An Overview

Cell Type-Specific Biomarkers of Systemic Sclerosis Disease Severity Capture Cell-Intrinsic and Cell-Extrinsic Circuits

Transcriptional insights into pathogenesis of cutaneous systemic sclerosis using pathway driven meta-analysis assisted by machine learning methods

Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics

Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms

Integrative Transcriptomic Analysis of Peripheral Blood Monocytes in Systemic Sclerosis and Shared Pathogenic Pathways in Autoimmune Diseases

A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis

Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis

Current Concepts on the Pathogenesis of Systemic Sclerosis

Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis

POS0847 IDENTIFICATION OF MOLECULAR PHENOTYPES IN SYSTEMIC SCLEROSIS BY INTEGRATIVE SYSTEMS ANALYSIS

P134 Developing a potential composite pharmacodynamic serum marker of skin severity in systemic sclerosis

A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis

Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers

Metabolic fingerprinting of systemic sclerosis: a systematic review